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Background: The aim of this review was to explore the existing body of literature focusing on the intralesional
treatments of keloids and hypertrophic scars.
Methods: A comprehensive systematic review of related articles was conducted across multiple databases. Article
selection was limited to those published in the English language between 1950 and 2014. Search terms for the
on-line research were “scar(s),” “keloid(s),” “hypertrophic,” “injection,” “intralesional,” and “treatment”.
Results: The initial search returned 2548 published articles. After full text review, the final search yielded 11 articles
that met inclusion criteria. A total of 14 patient samples in 11 articles were collected. The most frequent intralesional
injection treatment studied was triamcinolone (n = 5), followed by bleomycin (n = 3), 5-fluorouracil (n = 2), verapamil
(n = 2), cryosurgery, and collagenase. The scar height reduction for all but one study was demonstrated, with acceptable
complication and recurrence rate. Only three articles reported a follow-up period longer than 18 months, and only two
studies used standardized outcome criteria with a quantitative scale.
Conclusions: Although many treatment options have already been described in the literature, there is no universally
accepted treatment resulting in permanent hypertrophic or keloid scar ablation. The lack of adequately long-term
powered randomized controlled trials does not permit to establish definitive conclusions with implications for routine
clinical practice.
Level of evidence: III/Therapeutic
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The cicatrization results in a spectrum of scar formation
ranging from nearly scarless healing to excessive fibrosis
or atrophy. Pathological scars can be basically divided
into two main categories: (1) keloidal and hypertrophic
scars and (2) atrophic scars. While hypertrophic scars
are confined to the original injury and increase in size
by pushing outward and not by invasion, keloids are
characterized by scar tissue that extends beyond the
confines of the original wound. Hypertrophic scars* Correspondence: zhangyixin6688@hotmail.com
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article, unless otherwise stated.usually grow quickly (3–6 months) and after this period
can partially regress. On the contrary keloids have a long
(years), permanent, and uninterrupted evolution. The inci-
dence of hypertrophic scars and keloids varies with age,
race, sex, anatomic location, and the inciting trauma. Asso-
ciated symptoms such as pruritus, dysesthesia, and pain, as
well as restricted range of motion and contracture forma-
tion may be observed with both keloids and hypertrophic
scars but tend to be more prevalent with keloids [1, 2].
Historically, a variety of treatment approaches for keloids
and hypertrophic scars have been extensively described in
the literature. The methods are ranging from surgical to
non-surgical methods. Evidence supports occlusive dress-
ings, compression therapy, silicone sheeting, intralesional
corticosteroid injections, cryotherapy, surgical removal,icle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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verapamil, 5-fluorouracil, bleomycin, and interferon alfa-2b
injections [3, 4]. In some cases, when surgical approaches
are inadvisable, intralesional injection treatments play an
important role in the treatment of keloids.
Despite the large number of described techniques, scar
therapy is still challenging and controversial with a high
recurrence rate regardless of therapy (especially for ke-
loids). Through the literature retrieval, we have found
most of the literature that is available about the intrale-
sional injection treatment of hypertrophic scars and keloids.
The aim of this article is to systematically review the exist-
ing body of literature regarding the management of hyper-
trophic scars and keloids with intralesional injections.
Methods
Search strategy
A comprehensive systematic review of related articles
was conducted in January of 2014 using databases in-
cluding Medline, the Cochrane database, Google and
Google Scholar, Clinical Trials.gov, Current Contents,
and PubMed. Article selection was limited to those pub-
lished in the English language between January 1, 1950,
and January 15, 2014. Search terms for the on-line research
were a combination of the following: “scar(s),” “keloid(s),”
“hypertrophic,” “injection,” “intralesional,” “treatment”. Ref-
erence lists of selected articles, other related studies, and
review articles were examined for eligible studies. A
cross-referencing from identified articles and confer-
ence abstracts was also performed. Numerous articles
were identified through searches of the extensive files
of the authors. Abstracts and reports from meetings
were included only when they related directly to previ-
ously or subsequently published work.
Selection criteria
Three researchers (A.T.P., M.T., and D.L.) performed
the review process for inclusion in the initial review, and
the senior author (Y.X.Z.) acting as an arbiter solved all
the disagreement between them during the procedure.
General inclusion criteria consisted of articles discussing
injection treatments related to scar(s) and their outcomes.
The initial search returned 2548 published articles.
Specific inclusion criteria mandated retrospective or
prospective investigations that met all the following cri-
teria: 1. Papers published in the English language; 2.
clinical investigation assessing single-substance injection
treatment for hypertropic or keloid scars; 3. more than 5
patients included in the study; 4. clear description of the
nature of the injected substance; 5. clear description of
the nature (iatrogenic, post-traumatic, burn sequel), sites,
and age of the scar; 6. adequate follow-up (the average pa-
tient follow-up was limited to at least 6 months; a shorter
follow-up period was considered grossly inadequatebecause keloids can recur from months to years after
treatment).
Studies that solely discussed about injection techniques
were excluded as well as those in which combined treat-
ments (other-than-injection procedure associated to injec-
tion procedure(s)) and those investigations in which more
than one substance was injected to treat the scar.
After exclusion, 213 articles were selected for inclusion
in the initial review. A further screen excluded 150 pa-
pers because 14 of them had pertinent topic, but the
manuscript was written in other than English language,
10 discussed about scar not involving the skin, 17 were
related to non-human (laboratory and animal) studies,
54 presented multiple substance injections for the same
scar or intralesional injection treatment combined with
one or more different scar treatment (laser, surgery, RT,
compressive therapy, cryosurgery and electrochemother-
apy), 38 were reviews, 15 were paper describing single
case report or less than 5 cases, and 2 did not report the
exact number of patients included in the study. The
same researchers (A.T.P., M.T., and D.L.) reviewed the
remaining 63 articles in their entirety to ensure adequate
data content for inclusion. This final screen excluded 54
articles because 9 discussed about prophylactic treat-
ments for improvement of skin scarring [5–13], 12 did
not adequately describe the causes of the scars [14–25],
11 presented different kinds of scars such as atrophic or
depressed scars (10) [26–35] or cicatricial ectropion (1)
[36] which usually requires different treatment modal-
ities due to their different nature and characteristics, 1
did not adequately describe the type of the scar [37], 15
reported an inadequate average follow-up period (less
than 6 months) [4, 38–51], 3 did not adequately report
the follow-up period [52–54], 1 was a discussion of an-
other paper (already excluded due to the poor sample
population) [55], and 2 described a non-intralesional
treatment (Klinger et al. [56] reported the use of autolo-
gous fat graft inserted into the dermo-hypodermic junc-
tion, while Balkin [57] described the use of fluid silicone
injections under the scars). There were two articles lost
in the initial search, but they were cited in the articles
already included, so they were also selected for study
[58, 59]. After full text review, the final search yielded 11
articles that meet inclusion criteria and are thus pre-
sented in this review for analysis and data extraction
(Fig. 1 illustrates the literature review process) [58–68].
Data extraction
Data were extracted and then reviewed, and all reported
results were summarized to include common and clinic-
ally important outcomes. The following data were ex-
tracted from each primary article and used for descriptive
comparisons: author, year, study design, level of evidence,
mean age, sample size, number of treated scars, type of
Fig. 1 Citation attrition diagram
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cluding scar volume reduction, improvement of scar-
related symptoms, recurrence rate, local or systemic side
effects and follow-up periods (Table 2).
Results
Description of included studies
The articles included were published between 1966 and
2013. Sample sizes varied from 5 patients [63] to 50 pa-
tients [60]. The exact number of treated scars was not
reported in four studies [63–65, 67]. One article did not
provide any information on patient age [60]. In two
studies, the average age was not reported [59, 64]; in the
remaining nine studies, the sample population had a low
average patient age, between 16 and 32 years. Patient
age range was listed in all the articles, revealing ages be-
tween 1 and 74 years. Ten studies were prospective in-
vestigations [58, 60–69] and 1 was retrospective [59].
The level of evidence was II in three studies [61, 66, 67]
and IV in the remaining 8 [58–60, 62–65, 68]. Eight
studies described a single treatment in a single patient
sample [58–60, 62–65, 68]. Two articles described two dif-
ferent treatments in two separate patient samples [61, 67].
One study described two different treatment methods in
the same patient sample (the substances were injected in
two different areas of the same scar) [66]. A total of 16 pa-
tient samples in 13 articles were collected. The mostfrequent treatment studied was triamcinolone (five cases)
[59, 61, 64, 66, 67], followed by bleomycin (three cases)
[58, 60, 68], 5-fluorouracil (5-FU; two cases) [65, 66], ver-
apamil (two cases) [61, 67], cryosurgery [62], and collage-
nase [62]. All of these techniques were provided through
intralesional injections.
Outcomes, complications, and recurrences
The most commonly studied outcome measure was the
scar height reduction (percentage reduction from base-
line) that was usually classified by most authors by using
the following scale: complete flattening (100 %), significant
flattening (>75 %), moderate flattening (50–75 %), and
minimal flattening (<50 %). Furthermore, the method used
for scar height reduction assessment was investigated.
Other studied outcome measures included the reduction
of scar-related symptoms, complication rate associated
with every treatment, recurrence rate, and the follow-up
period. Table 2 summarizes all these data.
The scar height reduction for all but one study was
demonstrated. Only Kang et al. [63] obtained no changes
in scar volume after treatment of keloids and hyper-
trophic scars with intralesional injections of collagenase.
The use of Triamcinole was described in five cases
[59, 61, 64, 66, 67] with complete scar flattening ob-
served in four cases [59, 61, 64, 67]. The rates, where
provided, ranged from 51 to 100 % of patients with
Table 1 Management of hypertrophic scars and keloids: systematic review
Reference Sample size Study Randomization Controlled Comparative LOE Patients age Number of scars Treatment
Aggarwal H et al., 2008 [60] 50 patients Prospective No No No IV N.A. 50 Bleomycin
Ahuja RB and Chatterjee P, 2013 [61] 40 patients Prospective Yes No Yes II Average age: N.A. (range: 15–60) 22 Triamcinolone
26 Verapamil
Espana A et al., 2001 [58] 13 patients Prospective No No No IV Average age: 24 years (range: 14–36) 13 Bleomycin
Griffith BH, 1966 [59] 29 patients Retrospective No No No IV Average age: 22 years (range: 1–58) 37 Triamcinolone
Gupta S and Kumar B, 2001 [62] 12 patients Prospective No No No IV Average age: 31 years (range: 19–50) 12 Cryosurgery
Kang N et al., 2006 [63] 5 patients Prospective No No No IV Average age: 31 years (range: 12–46) N.A. Collagenase
Kiil J, 1977 [64] 44 patients Prospective No No No IV Average age: 16 years (range: 6–46) N.A. Triamcinolone
Kontochristopoulos et al., 2005 [65] 20 patients Prospective No No No IV Average age: 30 years (range: 12–65) N.A. 5-Fluorouracil
Manuskiatti W and Fitzpatrick RE, 2002 [66] 10 patients Prospective Yes No Yes II Average age: N.A. (range: 25–74) 10 5-Fluorouracil
Triamcinolone
Margareth Shanthi FX et al., 2008 [67] 54 patients Prospective Yes No Yes II Average age: 20 years (range: 10–50) N.A. Triamcinolone
Average age: 26 years (range: 10–50) N.A. Verapamil












Table 2 Outcomes and complications
Reference Volume reduction
(percent of lesions)




Recurrence rate Side effects Follow-up
(months)
Aggarwal H et al., 2008 [60] Complete flattening
(44 %)








(Bleomycin) Hyperpigmentation (14 %)
No particular histories (10)
Ahuja RB and Chatterjee P, 2013 [61] Complete flattening [VSS
mean value = 0] (100 %)
Foruncle/post-infective (14) VSS/Caliper – 0 % Pain (3 %) 6
Surgery (1) Teleangectasia (9 %)
Burns (4) Skin atrophy (18 %)
(Triamcinolone) Trauma (3)
(Verapamil) Complete flattening [VSS
mean value = 0] (100 %)




Espana A et al., 2001 [58] Complete flattening
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Kang N et al., 2006 [63] No changes in scar
volume
Infection (1), assault (1),
acne (2), coronary bypass
graft (1)
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Table 2 Outcomes and complications (Continued)
50 % flattening (40 %)
(5-Fluorouracil) 25 % flattening (10 %) Hyperpigmentation
(100 %)
0 % flattening (5 %)











Caliper – – Pain (100 %) 8
Hypopigmentation (20 %)
Telangiectasia (20 %)
Skin atrophy (10 %)
Margareth Shanthi FX et al., 2008 [67] Complete flattening [VSS
scale]
Acid burns, trauma, surgery,
acne, insect bite
VSS/Caliper – 0 % Hypo/hyperpigmentation 12
Menstrual irregularity(Triamcinolone)
(Verapamil) 97 % flattening [VSS
scale]
VSS/Caliper – 0 % Profuse sweating 12
Pain
Saray Y and Güleç AT, 2005 [68] Complete flattening
(73.3 %)





(67 %) and itching
(80 %)
0 % Pain (50 %) 19






Skin atrophy (21 %)
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served a significant flattening after 8 months of follow-
up without reporting the rate of flattening [66]. Of the
five studies included in the review, only two provided
specific data regarding the improvement of scar-related
symptoms [59, 64] with rates ranging from 41 to 93 %.
Most frequent side effects included pain (3 to 100 %,
where provided) reported in three studies, skin atrophy
(10 to 18 %) reported in three studies, hypo/hyperpig-
mentation (20 %, where provided) reported in two cases
and telangectasia (9 to 20 %) reported in two cases. No
recurrences were observed in three cases with a mean
follow-up ranging from 6 to 12 months. A recurrence
rate of 50 % was observed in one case with mean follow-
up of 60 months. One study did not provide this data.
All the three studies describing the use of bleomycin
[58, 60, 68] reported complete scar flattening with rates
ranging from 44 to 73.3 %. All these studies provided
data regarding the improvement of scar-related symp-
toms with rates ranging from 67 to 100 %. Most fre-
quent side effects included hyperpigmentation (14 to
29 %) reported in all studies, ulceration (16 to 100 %)
and pain (30 to 50 %) reported in two studies, and skin
atrophy reported in one case (21 %). Low recurrence
rates (14 and 15 %) were reported in two studies with
mean follow-up of 18 and 13 months, respectively, while
no recurrences were observed in another study after
19 months of follow-up.
The use of 5-FU was studied in two cases [65, 66].
One study reported a moderate (50 to 75 %) scar flatten-
ing in 80 % of patients; another study reported signifi-
cant flattening without providing the exact rate of
flattening. One investigation obtained complete reso-
lution of scar-related symptoms, whereas the second
study did not provide this data. Most frequent side ef-
fects included pain (100 %) reported in both the studies
and skin ulcerations (30 %) reported in one investiga-
tion. The recurrence rate was reported only in one paper
(47 %) with a mean follow-up of 12 months.
Verapamil was used in two cases [61, 67]; one study
reported a complete scar flattening in all the patients,
while the other study obtained a near total (97 %) scar
flattening (rate of patients not available). Both studies
did not provide any data regarding scar-related symp-
tom improvement. The most frequent side effect was
pain reported in both studies (3.5 %, where provided).
No recurrences were observed after 6 and 12 months
of follow-up.
Cryosurgery was reported in one study [62] with sig-
nificant (>75 %) scar flattening in 58 % of patients. This
study reported complete symptom resolution in all pa-
tients, with constant side effect (hypo-depigmentation)
in all treated patients. No recurrences were observed
after 9 months of follow-up.One article studied the use of collagenase [63], reveal-
ing this treatment as ineffective. Indeed, it reported no
changes in scar volume after 6 months follow-up. Data
regarding symptom resolution were not provided, while
several side effects (pain, blistering, skin ulceration,
swelling, and bruising) were observed in most patients.
Discussion
Keloids and hypertrophic scars represent an exuberant
healing response that poses a challenge for physicians; in
severe cases, they can produce dramatic cosmetic de-
formity and occasional functional problems. Although a
multitude of options exist in the literature on scar intra-
lesional therapy, currently no single therapy has consen-
sus approval. The literature itself is confusing because
there is no standardized method of reporting results and
as a clinician, sometimes it is really difficult to compare
results of several treatment options in a truly scientific
manner [17].
Some important aspects emerged from this systematic
review. In several articles, the number of patients inves-
tigated is slightly small: only in two manuscripts [60, 64]
the number of patients was more than 30 and only in
four articles is more than 20 [59, 60, 64, 67]. This lack of
large cohort studies is unexplainable considering that
intralesional treatment of hypertrophic scars and keloids
is quite common in the clinical practice and it is usually
performed in the outpatient office without requiring sur-
gery and hospitalization and thus is relatively inexpen-
sive. Furthermore, five articles did not provide any data
regarding the improvement of scar-related symptoms,
and four patient samples in three studies did not report
the exact rate of scar flattening, which are considered
two of the main outcome measures of scar treatment.
Only five articles reported the exact method used for
scar height measuring [61, 63, 66–68] and only two used
the Vancouver Scar Scale which is the standard scale
used universally for scar assessment [69].
Another important consideration was that nine patient
samples in seven articles had no scar recurrence and
two other samples had low recurrence rate (15 %).
Nevertheless, in all of these studies, the follow-up period
ranged from 6 to 18 months that is slightly inadequate
because keloids can recur from months to years after
treatment. Therefore, a 6-month-long period of observa-
tion cannot predict the scar’s tendency for hypertrophy
in a long term. It is therefore possible that the low recur-
rence rate observed in these studies could simply be re-
lated to the short follow-up period. Indeed, the absence
of recurrences observed by Ahuja and Chatterjee [61]
and by Griffith [59] with triamcinolone after 6 and
10 months of follow-up, respectively, grossly disagrees
with data collected by Kiil [64] that reported a high re-
currence rate (50 %) after 60 months of follow-up.
Trisliana Perdanasari et al. Burns & Trauma  (2015) 3:14 Page 8 of 10Furthermore, Nanda and Reddy [68] reported no recur-
rences with 5-FU after 6 months of follow-up, while
Kontochristopoulos et al [65] observed a high recurrence
rate (47 %) after 12 months of follow-up.
Limitation of the current investigation
The systematic review reported here combined data
across studies in order to estimate the effects of intrale-
sional treatments of hypertrophic scars and keloids with
more precision than is possible in a single study. The
main limitation of this systematic review is that the qual-
ity of the included papers varied. The level of evidence
of the included papers was II only in 3 studies [61, 66,
67] and IV in the remaining included investigations. In-
deed, 3 papers described randomized uncontrolled com-
parative trials [61, 66, 67], whereas the other 8 reported
one-treatment series without comparative or controlled
groups. None of the articles explicitly stated that analysis
of data adhered to the intention-to-treat principle, which
could lead to an overestimation of treatment effect in
these trials. The sample sizes were too small in all papers
to allow for an objective evaluation of treatment effect-
iveness with confidence. All studies had methodological
shortcomings and most lacked of appropriate statistical
methods. Although systematic reviews including only
randomized control trials may offer the best potential
evidence, it is possible that this method may neglect data
available from other papers. Therefore, the inclusion of
both randomized and nonrandomized trials collectively
has provided further information at the expense of the
level of evidence in this systematic review.
Implications for research and future perspective
As the treatment of keloids and hypertrophic scars is
still a challenge, it is clear that an adequate clinical
evaluation of these lesions before and after a treatment
by using standardized models is necessary. To best serve
the body of the literature on this topic, future studies re-
garding intralesional treatments of keloids and hyper-
trophic scars should have a focus on the following
principles. First, larger sample size, randomized, and
placebo-controlled studies are warranted. Second, the in-
clusion criteria should become stricter because of the
needing of highly selected patients according to medical
history, previous treatments, and site of the scar, with a
clear distinction between the nature (iatrogenic, trau-
matic, or burn causes) and the type of the scar (keloid
and hypertrophic scars). Third, more explicit details
about the assessment of the clinical outcomes should be
always reported, both for the volume reduction and for
the scar-related symptoms improvement. Fourth, the re-
sults should be based on a set of standardized outcome
criteria with quantitative scales and methods of outcome
evaluation to make the results comparable. Fifth, thefollow-up period should always be provided and, if pos-
sible, should always be longer as possible (at least
24 months) due to the high recurrence rate of these
types of lesions, especially for keloids.
Although the investigation and application of prevent-
ive measures remain a priority before, during, and im-
mediately after wound closure, future researches are
required to determine the mechanism of action for dif-
ferent injectable substances and to examine the efficacy
of as many quantifiable and objectivable parameters
as possible. In addition, further potential treatment
approaches in the field of intralesional non-injective
therapy alone such as nanotechnologies and molecular
therapies should be investigated in the clinical daily
practice.
Conclusions
The present systematic review summarized the current
evidence on the effectiveness of intralesional treatment
for keloid and hypertrophic scar. Although many treat-
ment options have already been described in the litera-
ture, there is no universally accepted treatment resulting
in permanent hypertrophic or keloid scar ablation. No
definitive conclusions with implications for routine clin-
ical practice could be highlighted regarding the effective-
ness of different techniques, due to the scarcity and low
quality of the included studies. Despite several studies
demonstrating encouraging results, the lack of the
abovementioned criteria makes it difficult to establish
the standard practice and identify the best technique en-
suring long-term effectiveness and low recurrence rates.
Therefore, adequately powered randomized controlled
trials should be recommended with an improvement of
the quality on the effectiveness of the intralesional injec-
tion therapies for hypertrophic and keloid scars to better
clarify these aspects.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Study design and conception of this manuscript were performed by ATP,
MT, LG, YXZ, and DL. Literature retrieving and study selection were
performed by ATP, MT, YXZ, and DL. Results analysis and interpretation are
done by ATP, MT, FN, TD, and DL. The manuscript was drafted by ATP, YXZ,
GDB, and DL, and ATP, MT, and LG contributed equally to this work. All
authors read and approved the final manuscript.
Financial disclosure
None of the authors has financial conflicts or interests to report in association
with the contents of this paper.
Author details
1Department of Plastic and Reconstructive Surgery, Shanghai Ninth People’s
Hospital, Shanghai JiaoTong University, School of Medicine, 639 Zhi Zao Ju
Road, 200011, Shanghai, P.R. China. 2Department of Plastic and Reconstructive
Surgery, Marche Polytechnic University Medical School, University Hospital of
Ancona, Ancona, Italy. 3Department of Plastic Reconstructive and Aesthetic
Surgery, University of Rome, Rome, Italy. 4Plastic Reconstructive and Aesthetic
Surgery Unit, Villa Salaria Clinic, Rome, Italy.
Trisliana Perdanasari et al. Burns & Trauma  (2015) 3:14 Page 9 of 10Received: 15 June 2015 Accepted: 13 August 2015
References
1. Tsao SS, Dover JS, Arndt KA, Kaminer MS. Scar management: keloid,
hypertrophic, atrophic, and acne scars. Semin Cutan Med Surg.
2002;21(1):46–75.
2. Carantino I, Florescu IP, Carantino A. Overview about the keloid scars and
the elaboration of a non-invasive, unconventional treatment. J Med Life.
2010;3(2):122–7.
3. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic
scars. Am Fam Physician. 2009;80(3):253–60.
4. Naeini FF, Najafian J, Ahmadpour K. Bleomycin tattooing as a promising
therapeutic modality in large keloids and hypertrophic scars. Dermatol Surg.
2006;32(8):1023–9. discussion 1029–30.
5. Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, et al. Use
of botulinum toxin type A to improve treatment of facial wounds: a
prospective randomised study. J Plast Reconstr Aesthet Surg.
2013;66(2):209–14.
6. Jablonka EM, Sherris DA, Gassner HG. Botulinum toxin to minimize facial
scarring. Facial Plast Surg. 2012;28(5):525–35.
7. McCollum PT, Bush JA, James G, Mason T, O'Kane S, McCollum C, et al.
Randomized phase II clinical trial of avotermin versus placebo for scar
improvement. Br J Surg. 2011;98(7):925–34.
8. Bush J, Duncan JA, Bond JS, Durani P, So K, Mason T, et al. Scar-improving
efficacy of avotermin administered into the wound margins of skin incisions
as evaluated by a randomized, double-blind, placebo-controlled, phase II
clinical trial. Plast Reconstr Surg. 2010;126(5):1604–15.
9. Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, et al. Prophylactic
administration of avotermin for improvement of skin scarring: three double-
blind, placebo-controlled, phase I/II studies. Lancet. 2009;373(9671):1264–74.
10. Ono I, Akasaka Y, Kikuchi R, Sakemoto A, Kamiya T, Yamashita T, et al. Basic
fibroblast growth factor reduces scar formation in acute incisional wounds.
Wound Repair Regen. 2007;15(5):617–23.
11. Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL,
et al. Botulinum toxin to improve facial wound healing: A prospective,
blinded, placebo-controlled study. Mayo Clin Proc. 2006;81(8):1023–8.
12. Wilson AM. Use of botulinum toxin type A to prevent widening of facial
scars. Plast Reconstr Surg. 2006;117(6):1758–66.
13. Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the
prevention of keloid scar recurrence. Arch Facial Plast Surg. 2005;7(3):172–5.
14. Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional
triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of
keloids. Dermatol Surg. 2012;38(1):104–9.
15. Anthony ET, Lemonas P, Navsaria HA, Moir GC. The cost effectiveness of
intralesional steroid therapy for keloids. Dermatol Surg. 2010;36(10):1624–6.
16. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional
botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg.
2009;33(3):409–12.
17. Haurani MJ, Foreman K, Yang JJ. Siddiqui A.5-Fluorouracil treatment of
problematic scars. Plast Reconstr Surg. 2009;123(1):139–48.
18. Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment
with triamcinolone acetonide intralesional injection. Int J Dermatol.
2008;47(2):183–6.
19. Beuth J, Hunzelmann N, Van Leendert R, Basten R, Noehle M, Schneider B.
Safety and efficacy of local administration of contractubex to hypertrophic
scars in comparison to corticosteroid treatment. Results of a multicenter,
comparative epidemiological cohort study in Germany. In Vivo.
2006;20(2):277–83.
20. Muneuchi G, Suzuki S, Onodera M, Ito O, Hata Y, Igawa HH. Long-term
outcome of intralesional injection of triamcinolone acetonide for the
treatment of keloid scars in Asian patients. Scand J Plast Reconstr Surg
Hand Surg. 2006;40(2):111–6.
21. Yosipovitch G, Widijanti Sugeng M, Goon A, Chan YH, Goh CL. A
comparison of the combined effect of cryotherapy and corticosteroid
injections versus corticosteroids and cryotherapy alone on keloids: a
controlled study. J Dermatolog Treat. 2001;12(2):87–90.
22. Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the
treatment of keloids. Dermatology. 2002;204(2):130–2.
23. Ahmad K. Regression in keloid scar by intralesional injection of papaya milk.
Br J Plast Surg. 1998;51(3):261.24. Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of
keloids. Dermatol Surg. 2004;30(1):54–6.
25. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new
treatment measure for keloids. Plast Reconstr Surg. 2009;124(5):275e–7e.
26. Munavalli GS, Smith S, Maslowski JM, Weiss RA. Successful treatment of
depressed, distensible acne scars using autologous fibroblasts: a multi-site,
prospective, double blind, placebo-controlled clinical trial. Dermatol Surg.
2013;39(8):1226–36.
27. Mazzola IC, Cantarella G, Mazzola RF. Management of tracheostomy scar by
autologous fat transplantation: a minimally invasive new approach.
J Craniofac Surg. 2013;24(4):1361–4.
28. Khan F, Richards K, Rashid RM. Hyaluronic acid filler for a depressed scar.
Dermatol Online J. 2012;18(5):15.
29. Kim JE, Lee OS, Choi J, Son SW, Oh CH. The efficacy of stereoimage optical
topometry to evaluate depressed acne scar treatment using cultured
autologous fibroblast injection. Dermatol Surg. 2011;37(9):1304–13.
30. Guisantes E, Fontdevila J, Rodríguez G. Autologous fat grafting for
correction of unaesthetic scars. Ann Plast Surg. 2012;69(5):550–4.
31. Sage RJ, Lopiccolo MC, Liu A, Mahmoud BH, Tierney EP, Kouba DJ.
Subcuticular incision versus naturally sourced porcine collagen filler for acne
scars: a randomized split-face comparison. Dermatol Surg. 2011;37(4):426–31.
32. Hasson A, Romero WA. Treatment of facial atrophic scars with Esthélis, a
hyaluronic acid filler with polydense cohesive matrix (CPM). J Drugs
Dermatol. 2010;9(12):1507–9.
33. Epstein RE, Spencer JM. Correction of atrophic scars with artefill: an
open-label pilot study. J Drugs Dermatol. 2010;9(9):1062–4.
34. Beer K. A single-center, open-label study on the use of injectable poly-L-lactic
acid for the treatment of moderate to severe scarring from acne or varicella.
Dermatol Surg. 2007;33 Suppl 2:S159–67.
35. Barnett JG, Barnett CR. Treatment of acne scars with liquid silicone
injections: 30-year perspective. Dermatol Surg. 2005;31(11 Pt 2):1542–9.
36. Fezza JP. Nonsurgical treatment of cicatricial ectropion with hyaluronic acid
filler. Plast Reconstr Surg. 2008;121(3):1009–14.
37. Gentile P, De Angelis B, Pasin M, Cervelli G, Curcio CB, Floris M, et al.
Adipose-derived stromal vascular fraction cells and platelet-rich plasma:
basic and clinical evaluation for cell-based therapies in patients with scars
on the face. J Craniofac Surg. 2014;25(1):267–72.
38. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in
combination with 5-fluorouracil for the treatment of keloid and
hypertrophic scars. Clin Exp Dermatol. 2009;34(2):219–23.
39. Koc E, Arca E, Surucu B, Kurumlu Z. An open, randomized, controlled,
comparative study of the combined effect of intralesional triamcinolone
acetonide and onion extract gel and intralesional triamcinolone acetonide
alone in the treatment of hypertrophic scars and keloids. Dermatol Surg.
2008;34(11):1507–14.
40. Berman B, Patel JK, Perez OA, Viera MH, Amini S, Block S, et al. Evaluating
the tolerability and efficacy of etanercept compared to triamcinolone
acetonide for the intralesional treatment of keloids. J Drugs Dermatol.
2008;7(8):757–61.
41. Kelemen O, Hegedus G, Kollár L, Menyhei G, Seress L. Morphological
analysis of the connective tissue reaction in linear hypertrophic scars
treated with intralesional steroid or silicone-gel sheeting. A light and
electron microscopic study. Acta Biol Hung. 2008;59(2):129–45.
42. Ardehali B, Nouraei SA, Van Dam H, Dex E, Wood S, Nduka C. Objective
assessment of keloid scars with three-dimensional imaging: quantifying
response to intralesional steroid therapy. Plast Reconstr Surg.
2007;119(2):556–61.
43. Asilian A, Darougheh A, Shariati F. New combination of triamcinolone,
5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic
scars. Dermatol Surg. 2006;32(7):907–15.
44. Al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature
keloids. Int J Dermatol. 1996;35(7):515–7.
45. Krusche T, Worret WI. Mechanical properties of keloids in vivo during
treatment with intralesional triamcinolone acetonide. Arch Dermatol Res.
1995;287(3–4):289–93.
46. Wong TW, Chiu HC, Yip KM. Intralesional interferon alpha-2b has no effect
in the treatment of keloids. Br J Dermatol. 1994;130(5):683–5.
47. Pittet B, Rubbia-Brandt L, Desmoulière A, Sappino AP, Roggero P, Guerret S,
et al. Effect of gamma-interferon on the clinical and biologic evolution of
hypertrophic scars and Dupuytren's disease: an open pilot study. Plast
Reconstr Surg. 1994;93(6):1224–35.
Trisliana Perdanasari et al. Burns & Trauma  (2015) 3:14 Page 10 of 1048. Layton AM, Yip J, Cunliffe WJ. A comparison of intralesional triamcinolone
and cryosurgery in the treatment of acne keloids. Br J Dermatol.
1994;130(4):498–501.
49. Sproat JE, Dalcin A, Weitauer N, Roberts RS. Hypertrophic sternal scars:
silicone gel sheet versus Kenalog injection treatment. Plast Reconstr Surg.
1992;90(6):988–92.
50. Larrabee Jr WF, East CA, Jaffe HS, Stephenson C, Peterson KE. Intralesional
interferon gamma treatment for keloids and hypertrophic scars. Arch
Otolaryngol Head Neck Surg. 1990;116(10):1159–62.
51. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, et al. A controlled
trial of intralesional recombinant interferon-gamma in the treatment of
keloidal scarring. Clinical and histologic findings. Arch Dermatol.
1990;126(10):1295–302.
52. Isaac C, Carvalho VF, Paggiaro AO, de Maio M, Ferreira MC. Intralesional
pentoxifylline as an adjuvant treatment for perioral post-burn hypertrophic
scars. Burns. 2010;36(6):831–5.
53. Lee RC, Doong H, Jellema AF. The response of burn scars to intralesional
verapamil. Report of five cases. Arch Surg. 1994;129(1):107–11.
54. Ketchum LD, Smith J, Robinson DW, Masters FW. The treatment of
hypertrophic scar, keloid and scar contracture by triamcinolone acetonide.
Plast Reconstr Surg. 1966;38(3):209–18.
55. Patel N. Fat injection in severe burn outcomes: a new perspective of scar
remodeling and reduction. Aesthetic Plast Surg. 2008;32(3):470–2.
56. Klinger M, Caviggioli F, Klinger FM, Giannasi S, Bandi V, Banzatti B, et al.
Autologous fat graft in scar treatment. J Craniofac Surg. 2013;24(5):1610–5.
57. Balkin SW. Treatment of painful scars on soles and digits with injections of
fluid silicone. J Dermatol Surg Oncol. 1977;3(6):612–4.
58. España A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and
hypertrophic scars by multiple needle punctures. Dermatol Surg.
2001;27(1):23–7.
59. Griffith BH. The treatment of keloids with triamcinolone acetonide. Plast
Reconstr Surg. 1966;38(3):202–8.
60. Aggarwal H, Saxena A, Lubana PS, Mathur RK, Jain DK. Treatment of keloids
and hypertrophic scars using bleom. J Cosmet Dermatol. 2008;7(1):43–9.
61. Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil
hydrochloride and triamcinolone acetonide in hypertrophic scars and
keloids. Burns. 2014;40(4):583–8.
62. Gupta S, Kumar B. Intralesional cryosurgery using lumbar puncture and/or
hypodermic needles for large, bulky, recalcitrant keloids. Int J Dermatol.
2001;40(5):349–53.
63. Kang N, Sivakumar B, Sanders R, Nduka C, Gault D. Intra-lesional injections
of collagenase are ineffective in the treatment of keloid and hypertrophic
scars. J Plast Reconstr Aesthet Surg. 2006;59(7):693–9.
64. Kiil J. Keloids treated with topical injections of triamcinolone acetonide
(kenalog). Immediate and long-term results. Scand J Plast Reconstr Surg.
1977;11(2):169–72.
65. Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, Stefanaki K,
Argyrakos T, Petridis A, et al. Intralesional 5-fluorouracil in the treatment of
keloids: an open clinical and histopathologic study. J Am Acad Dermatol.
2005;52(3 Pt 1):474–9.
66. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and
hypertrophic sternotomy scars: comparison among intralesional
corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye
laser treatments. Arch Dermatol. 2002;138(9):1149–55.
67. Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional
verapamil with intralesional triamcinolone in the treatment of hypertrophic
scars and keloids. Indian J Dermatol Venereol Leprol. 2008;74(4):343–8.
68. Saray Y, Güleç AT. Treatment of keloids and hypertrophic scars with
dermojet injections of bleomycin: a preliminary study. Int J Dermatol.
2005;44(9):777–84.
69. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and
its interrater reliability. Burn Care Rehabil. 1995;16:535–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
